UBE2C and cervical cancer: Treatment of cervical cancer cells with vorinostat, a histone deacetylase inhibitor that reduces PI3K/AKT/mTOR signaling and UBE2C activation, reverses EMT through downregulation of N-cadherin and vimentin and upregulation of E-cadherin [124].